Salmeterol/fluticasone combination (SFC) is associated with improved asthma control compared with concurrent long-acting β2 agonists (LABA) and inhaled corticosteroids (ICS) or ICS alone Source: Eur Respir J 2003; 22: Suppl. 45, 235s Year: 2003
The impact of tiotropium on mortality when added to inhaled corticosteroids and long-acting beta agonist therapy in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017
Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients? Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004
Initiation of treatment with the salmeterol/fluticasone propionate (FP) combination product is better than inhaled steroid alone (FP) in asthmatic patients symptomatic on short-acting bronchodilator alone Source: Eur Respir J 2003; 22: Suppl. 45, 410s Year: 2003
Triple therapy of umeclidinium and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Safety of fluticasone furoate (FF), an inhaled corticosteroid in combination with vilanterol (VI), a long-acting beta agonist in management of COPD exacerbations Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids}, Source: Eur Respir J 2012; 40: 570-579 Year: 2012
Efficacy and safety of inhaled corticosteroid‘s (ICS) and long-acting beta-agonist‘s (LABA) combination in asthma (A) patients Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004
Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe-to-very severe COPD Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005
Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) versus similar ICS dose in children and adults with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Is the combination of long-acting β2 -agonists (LABA) and inhaled steroids (ICS) superior to higher ICS dose in children and adults with persistent asthma? Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA) Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012
Improved control and compliance in children is achieved with salmeterol/fluticasone combination (SFC) compared with concurrent long-acting β2 agonists (LABA) + inhaled corticosteroids (ICS) Source: Eur Respir J 2003; 22: Suppl. 45, 312s Year: 2003
Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021
Addition of tiotropium (T) to a regular treatment with long-acting β-agonist+inhaled corticosteroid (LABA+ICS) in patients with severe to very-severe COPD under in-patient pulmonary rehabilitation program (PRP) Source: Annual Congress 2009 - Pulmonary rehabilitation: extending the scope and benefit of rehabilitation for patients with chronic respiratory disease Year: 2009
Improved patient compliance with salmeterol/fluticasone propionate combination (SFC) compared with regular long-acting β2 agonist (LAB) and inhaled steroid (IS) therapy Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002